Gemphire Therapeutics (GEMP) Set to Announce Quarterly Earnings on Thursday

Gemphire Therapeutics (NASDAQ:GEMP) is set to issue its quarterly earnings data after the market closes on Thursday, March 15th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.

Shares of Gemphire Therapeutics (NASDAQ:GEMP) traded down $0.16 during trading hours on Wednesday, hitting $7.33. 35,636 shares of the company were exchanged, compared to its average volume of 134,573. The firm has a market cap of $104.56, a P/E ratio of -2.17 and a beta of 4.66. The company has a quick ratio of 4.17, a current ratio of 4.17 and a debt-to-equity ratio of 1.00. Gemphire Therapeutics has a 1-year low of $6.07 and a 1-year high of $21.59.

In other Gemphire Therapeutics news, insider Steven R. Ph.D. Gullans bought 71,429 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average cost of $7.00 per share, with a total value of $500,003.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 34.00% of the stock is currently owned by corporate insiders.

An institutional investor recently raised its position in Gemphire Therapeutics stock. Vanguard Group Inc. increased its holdings in shares of Gemphire Therapeutics Inc (NASDAQ:GEMP) by 137.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,898 shares of the company’s stock after purchasing an additional 17,892 shares during the quarter. Vanguard Group Inc. owned 0.29% of Gemphire Therapeutics worth $399,000 as of its most recent filing with the SEC. 20.40% of the stock is owned by institutional investors.

GEMP has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target (up from $21.00) on shares of Gemphire Therapeutics in a research report on Tuesday, November 14th. Zacks Investment Research upgraded shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Thursday, November 16th. Roth Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Gemphire Therapeutics in a research report on Friday, December 22nd. Finally, ValuEngine downgraded shares of Gemphire Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 8th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $22.75.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Earnings History for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply